Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00BWF
|
||||
| Former ID |
DNCL001689
|
||||
| Drug Name |
AGN-XX/YY
|
||||
| Synonyms |
Rezatomidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetic nephropathy; Fibromyalgia [ICD9: 250.4, 729.1; ICD10:E11.21, M79.7] | Phase 2 | [1] | ||
| Company |
ACADIA Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H16N2S
|
||||
| Canonical SMILES |
CC1=C(C(=CC=C1)C(C)C2=CNC(=S)N2)C
|
||||
| InChI |
1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
|
||||
| InChIKey |
WQXVKEDUCPMRRI-JTQLQIEISA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of ACADIA Pharmaceuticals. | ||||
| REF 2 | Patent WO2008058220 A2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.